# Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers

> **NCT04238663** · PHASE1 · COMPLETED · sponsor: **mAbxience Research S.L.** · enrollment: 115 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** MB02 (Bevacizumab Biosimilar)
- **DRUG:** EU approved Avastin®
- **DRUG:** US licenced Avastin®

## Key facts

- **NCT ID:** NCT04238663
- **Lead sponsor:** mAbxience Research S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-24
- **Primary completion:** 2020-03-17
- **Final completion:** 2020-03-17
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2023-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04238663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04238663, "Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04238663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*